Elanco Animal Health Inc: Form 10-Q for the period ended Sep 30, 2023
Filed with the SEC on Nov 7, 2023 and accepted by EDGAR at Nov 7, 2023, 16:14 ET.
Management's discussion and analysis
As filed, 37,521 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Introduction
Management’s discussion and analysis of financial condition and results of operations (MD&A) is intended to assist the reader in understanding and assessing significant changes and trends related to our results of operations and financial position. This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying footnotes in Item 1 of Part I of this Form 10-Q. Certain statements in this Item 2 of Part I of this Form 10-Q constitute forward-looking statements. Various risks and uncertainties, including those discussed in "Forward-Looking Statements" of this Form 10-Q, in Item 1A, "Risk Factors" of Part II of this Form 10-Q, and in Item 1A, “Risk Factors” of Part I of our 2022 Form 10-K, may cause our actual results, financial position and cash generated from operations to differ materially from these forward-looking statements. Further, due to the seasonality of our pet health sales, interim results are not necessarily an appropriate base from which to project annual results.
Business Overview
Elanco is a global animal health company that develops products for pets and farm animals in more than 90 countries. With a heritage dating back to 1954, we rigorously innovate to improve the health of animals and to benefit our customers while fostering an inclusive, cause-driven culture for our employees. We operate our business in a single segment directed at fulfilling our vision of enriching the lives of people through food, making protein more accessible and affordable, and through pet companionship, helping pets live longer, healthier lives. We advance our vision by offering products in the Pet Health and Farm Animal product categories.
We offer a diverse portfolio of approximately 200 brands that make us a trusted partner to pet owners, veterinarians and farm animal producers. Our products are generally sold worldwide to third-party distributors and independent retailers and directly to farm animal producers and veterinarians. With the acquisition of Bayer Animal Health in 2020, we expanded our presence in retail and e-commerce channels, allowing our customers to shop where and how they want.
Key Trends and Factors Affecting Our Results of Operations
Acquisition and Integration Activity: To date in 2023, we have acquired certain U.S. marketed products, pipeline products, inventory and an assembled workforce from NutriQuest, LLC (NutriQuest) and certain assets including inventory and distribution rights for certain marketed products from NutriQuest Nutricao Animal Ltda (NutriQuest Brazil). Additionally, as previously disclosed, in April 2023, we successfully completed the integration of the Bayer Animal Health business into Elanco's Enterprise Resource Planning (ERP) system. During the nine months ended September 30, 2023, we incurred costs totaling $86 million related to integration activities, including the build out of processes and systems to support our global organization. We anticipate some additional costs through early 2024 as we finalize these integration activities.
Macroeconomic Factors: Our operations are exposed to and are impacted by various global macroeconomic factors. We face continuing market and operating challenges across the globe due to, among other factors, the Russia-Ukraine conflict, conditions related to the COVID-19 pandemic, supply chain disruption, higher interest rates and inflationary pressures. Continued evolution of these conditions has led to economic slowdowns in certain countries and/or regions and volatility in consumer behavior. Additionally, as discussed in more detail below, the continued rise in interest rates throughout the year, specifically in long-term treasury rates in the third quarter, led to a $1,042 million pre-tax impairment charge as of September 30, 2023. We anticipate global macroeconomic pressures to continue beyond 2023.
Russia-Ukraine Conflict: As a global animal health leader, we have an obligation to support the health of animals and people. At the center of that work is ensuring access and availability of food and avoiding the spread of disease. At this time, we are limiting our business in Russia to only the essential products that support these needs, while complying with all imposed sanctions. We do not currently manufacture products in Russia, but we continue to support the health of animals and people in the country. We have entered into an agreement pursuant to which we will supply raw material inventories to an entity in Russia that will manufacture its own products, which we will then distribute, because of new laws requiring products sold in Russia to be produced there as well. We do not conduct business with the Russian government. During the nine months ended September 30, 2023, revenue from Russian and Ukrainian customers represented approximately 1% of our consolidated revenue. Assets held in Russia as of September 30, 2023, represented less than 1% of our consolidated assets.
Seasonality: While many of our products are sold consistently throughout the year, we do experience seasonality in our pet health business due to increased demand for certain parasiticide product offerings in the first half of the year. For example, based upon historical results, approximately 75% and 60% of total annual revenue contributed by our higher-margin parasiticide products Seresto and Advantage Family, respectively, typically occurs during the first half of the year, which is reflective of the flea and tick season in the Northern Hemisphere.
Product Development and Regulatory Update
A key element of our targeted value creation strategy is to drive growth through portfolio development and product innovation. We continue to pursue the development of new chemical and biological molecules through our approach to innovation. Our future growth and success depend on both our pipeline of new products, including new products that we develop internally and may develop with partners and products that we are able to obtain through licenses or acquisitions, and the life cycle management of our existing products. We believe we are an industry leader in animal health R&D, with a track record of successful product innovation, business development and commercialization. For example, in July 2023, we launched our canine parvovirus monoclonal antibody in the U.S. after receiving conditional approval from the U.S. Department of Agriculture. This product is the first and only approved therapeutic solution to treat canine parvovirus, one of the most contagious and deadly viruses a dog can contract.
Seresto: On July 13, 2023, the EPA announced its completion of a comprehensive, multi-year review, with support from the FDA, of the Seresto flea and tick collar and confirmed the continued registration of the collar. As part of the EPA’s scientific review process, the agency analyzed incident data including third-party assessments and compared data to other EPA-registered pet products. Based on comprehensive data from the study, the EPA concluded that Seresto continues to meet all the EPA’s standards for registration under the Federal Insecticide, Fungicide and Rodenticide Act (FIFRA), which ensures that products do not pose an unreasonable risk of harm. We believe the EPA's conclusions align with those of authorities worldwide, with Seresto being approved for use in more than 80 countries and supported by veterinary professionals around the globe. The robust scientific evidence continues to support Seresto's safe use.
Goodwill Impairment Charge
Given the sharp increase in long-term treasury rates in the third quarter of 2023, we assessed our long-lived assets for impairment, concluding that qualitative impairment indicators (i.e., a triggering event) existed as of September 30, 2023, for certain indefinite-lived assets, including goodwill. Accordingly, we performed an interim quantitative goodwill impairment test. Significant management judgment was required in estimating our reporting unit’s fair value and in the creation of forecasts of future operating results that were used in the discounted cash flow method of valuation. These included, but were not limited to, estimates and assumptions regarding our future cash flows, revenue growth and other profitability measures such as gross margin and EBITDA margin; and the determination of an appropriate discount rate. We made these significant judgments based on our historical experience, relevant market size, historical pricing and expected industry trends.
Due principally to the sharp increase in long-term treasury rates in the third quarter of 2023, which led to an increased discount rate assumption relative to prior interim assessments, our quantitative test resulted in a $1,042 million pre-tax impairment charge. While we believe the estimates and assumptions underlying our goodwill impairment test were reasonable in view of all available information, future changes in our discount rate assumption, whether driven by increases in long-term treasury rates or other factors, or future changes in other significant assumptions or the use of alternative estimates and assumptions, could have a significant impact on our reporting unit's estimated fair value and may expose us to further goodwill impairment losses. For additional information regarding this goodwill impairment, see Note 11. Goodwill to the condensed consolidated financial statements.
Results of Operations
The following discussion and analysis of our results of operations should be read along with our condensed consolidated financial statements and the notes thereto.
Revision of Prior Period Financial Statements Primarily Relating to Tax Valuation Allowance Adjustment
In connection with the preparation of our financial statements as of and for the year ended December 31, 2022, a cumulative error was identified relating to the valuation allowance for taxes for a Southeast Asia affiliate. While immaterial to prior years, correcting this cumulative error in 2022 would have caused the 2022 financial statements to be materially misstated. As a result of having to make the revisions related to this error, we made other immaterial revisions to our 2022 unaudited interim consolidated financial statements. All of the revisions have been reflected throughout this Form 10-Q.
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Revenue | $1,068 | $1,026 | 4% | $3,382 | $3,426 | (1)% |
| Costs, expenses and other: | ||||||
| Cost of sales | 487 | 472 | 3% | 1,415 | 1,465 | (3)% |
| % of revenue | 46% | 46% | —% | 42% | 43% | (1)% |
| Research and development | 86 | 78 | 10% | 248 | 241 | 3% |
| % of revenue | 8% | 8% | —% | 7% | 7% | —% |
| Marketing, selling and administrative | 313 | 298 | 5% | 993 | 963 | 3% |
| % of revenue | 29% | 29% | —% | 29% | 28% | 1% |
| Amortization of intangible assets | 140 | 128 | 9% | 410 | 398 | 3% |
| % of revenue | 13% | 12% | 1% | 12% | 12% | 1% |
| Asset impairment, restructuring and other special charges | 16 | 26 | (38)% | 91 | 152 | (40)% |
| Goodwill impairment | 1,042 | — | 100% | 1,042 | — | 100% |
| Interest expense, net of capitalized interest | 72 | 60 | 20% | 210 | 179 | 17% |
| Other expense, net | 9 | 8 | 13% | 41 | 11 | NM |
| (Loss) income before income taxes | (1,097) | (44) | NM | (1,068) | 17 | NM |
| % of revenue | (103)% | (4)% | NM | (32)% | —% | NM |
| Income tax (benefit) expense | (1) | 21 | NM | 22 | 41 | NM |
| Net loss | $(1,096) | $(65) | NM | $(1,090) | $(24) | NM |
Certain amounts and percentages may reflect rounding adjustments.
NM - Not meaningful
Revenue
As a global company, our products are sold in more than 90 countries, and as a result, significant portions of our revenue and expenses are recorded in currencies other than the U.S. dollar. As a result, our revenue is influenced by changes in foreign exchange rates. During the nine months ended September 30, 2023 and 2022, approximately 51% of our revenue was denominated in foreign currencies. Foreign currency movements decreased revenue by 1% and 2% for the three and nine months ended September 30, 2023, respectively, compared to the same periods in 2022.
Further, increases or decreases in inventory levels in our distribution channels can positively or negatively impact our quarterly revenue results, leading to variations in revenue. This can be a result of various factors, such as end customer demand, new customer contracts, heightened and generic competition, the need for certain inventory levels, our ability to renew distribution contracts with expected terms, our ability to implement commercial strategies, regulatory restrictions, unexpected customer behavior, proactive measures taken by us in response to shifting market dynamics, payment terms we extend, which are subject to internal policies, blackout shipping periods due to system downtime, implementations and integrations and procedures and environmental factors beyond our control.
On a global basis, our revenue by product category for the three and nine months ended September 30, 2023 and 2022 is summarized as follows:
(Dollars in millions)
| Three Months Ended September 30, Revenue 2023 | 2022 | % of Total Revenue 2023 | 2022 | Increase (Decrease) $ Change | % Change | CC (1) | |
|---|---|---|---|---|---|---|---|
| Pet Health | $495 | $469 | 46% | 46% | $26 | 6% | 6% |
| Farm Animal | 561 | 545 | 53% | 53% | 16 | 3% | 4% |
| Subtotal | 1,056 | 1,014 | 99% | 99% | 42 | 4% | 5% |
| Contract Manufacturing (2) | 12 | 12 | 1% | 1% | — | —% | (2)% |
| Total | $1,068 | $1,026 | 100% | 100% | 42 | 4% | 5% |
2023 Q3 Form 10-Q | 23
(Dollars in millions)
| Nine Months Ended September 30, Revenue 2023 | 2022 | % of Total Revenue 2023 | 2022 | Increase (Decrease) $ Change | % Change | CC (1) | |
|---|---|---|---|---|---|---|---|
| Pet Health | $1,688 | $1,718 | 50% | 50% | $(30) | (2)% | —% |
| Farm Animal | 1,661 | 1,667 | 49% | 49% | (6) | —% | 2% |
| Subtotal | 3,349 | 3,385 | 99% | 99% | (36) | (1)% | 1% |
| Contract Manufacturing (2) | 33 | 41 | 1% | 1% | (8) | (20)% | (18)% |
| Total | $3,382 | $3,426 | 100% | 100% | (44) | (1)% | 1% |
Note: Numbers may not add due to rounding
(1) Constant Currency (CC), a non-GAAP measure, is defined as revenue growth excluding the impact of foreign exchange rates. The calculation assumes the same foreign currency exchange rates that were in effect for the comparable prior-year period were used in translation of the current period results. We believe this metric provides a useful comparison to previous periods.
(2) Represents revenue from arrangements in which we manufacture products on behalf of a third-party.
The effects of price, foreign exchange rates and volume on changes in revenue for the three and nine months ended September 30, 2023 were as follows:
| Three months ended September 30, 2023 (Dollars in millions) | Revenue | Price | FX Rate | Volume | Total | CC |
|---|---|---|---|---|---|---|
| Pet Health | $495 | 4% | —% | 2% | 6% | 6% |
| Farm Animal | 561 | 3% | (1)% | 1% | 3% | 4% |
| Subtotal | 1,056 | 4% | (1)% | 1% | 4% | 5% |
| Contract Manufacturing | 12 | —% | 2% | (2)% | —% | (2)% |
| Total | $1,068 | 4% | (1)% | 1% | 4% | 5% |
| Nine months ended September 30, 2023 (Dollars in millions) | Revenue | Price | FX Rate | Volume | Total | CC |
|---|---|---|---|---|---|---|
| Pet Health | $1,688 | 5% | (2)% | (5)% | (2)% | —% |
| Farm Animal | 1,661 | 4% | (2)% | (2)% | —% | 2% |
| Subtotal | 3,349 | 4% | (2)% | (3)% | (1)% | 1% |
| Contract Manufacturing | 33 | —% | (2)% | (18)% | (20)% | (18)% |
| Total | $3,382 | 4% | (2)% | (3)% | (1)% | 1% |
Note: Numbers may not add due to rounding
Pet Health revenue increased $26 million, or 6%, for the three months ended September 30, 2023, compared to the same period in 2022, driven primarily by increased pricing, improved market conditions in Europe impacting parasiticide sales and improved supply for vaccines in the U.S. These factors were partially offset by competitive pressure on certain products in the U.S. veterinary channel. Pet Health revenue decreased $30 million, or 2%, for the nine months ended September 30, 2023, compared to the same period in 2022, driven by the unfavorable impact of foreign exchange rates and lower volumes, partially offset by increased pricing. For the nine months ended September 30, 2023, lower volumes were attributable to declines in demand for retail parasiticide products in Spain and continued competitive pressure on certain parasiticide products in the U.S. These factors were partially offset by higher demand for pain and over-the-counter products in the U.S. and increased revenue from new products.
Farm Animal revenue increased $16 million, or 3%, for the three months ended September 30, 2023, compared to the same period in 2022, driven by increased pricing and higher volumes, partially offset by an unfavorable impact from foreign exchange rates. Increased volumes were driven by revenue from new products, led by Experior, and strength in European poultry, partially offset by regulatory changes impacting cattle implant products and timing of U.S. poultry rotations. Farm Animal revenue decreased $6 million, flat on a percentage basis, for the nine months ended September 30, 2023, compared to the same period in 2022, impacted by lower volumes and the unfavorable impact of foreign exchange rates, which were offset by increased pricing. Lower volumes for the nine months ended September 30, 2023, were attributable to supply disruptions in U.S. cattle vaccines, reduced sales of cattle implants due to U.S. regulatory changes, timing of poultry rotations in the U.S. and generic competition. These factors were partially offset by increased revenue from new products, led by Experior, and strength in European poultry and Aqua.
Cost of Sales
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Cost of sales | $487 | $472 | 3% | $1,415 | $1,465 | (3)% |
| % of revenue | 46% | 46% | 42% | 43% |
Cost of sales increased $15 million for the three months ended September 30, 2023, primarily due to higher volume compared to the same period in the prior year, while cost of sales as a percentage of revenue was flat year over year. Product price increases and the impact of foreign exchange rates on international inventories sold were largely offset by inflation and planned reduced throughput at certain manufacturing sites in support of efforts to reduce inventory balances and improve cash conversion.
Cost of sales decreased $50 million for the nine months ended September 30, 2023, primarily due to lower volume compared to the same period in the prior year. Cost of sales as a percentage of revenue decreased from 43% for the nine months ended September 30, 2022, to 42% for the nine months ended September 30, 2023, due to a combination of product price increases and the impact of foreign exchange rates on international inventories sold, partially offset by inflation and planned reduced throughput at certain manufacturing sites in support of efforts to reduce inventory balances and improve cash conversion.
Research and Development
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Research and development | $86 | $78 | 10% | $248 | $241 | 3% |
| % of revenue | 8% | 8% | 7% | 7% |
Research and development expenses increased $8 million and $7 million for the three and nine months ended September 30, 2023, respectively, as compared to the same periods in the prior year, primarily driven by higher employee-related expenses, project costs and the unfavorable impact of foreign exchange rates impacting our European research and development sites.
Marketing, Selling and Administrative
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Marketing, selling and administrative | $313 | $298 | 5% | $993 | $963 | 3% |
| % of revenue | 29% | 29% | 29% | 28% |
Marketing, selling and administrative expenses increased $15 million and $30 million for the three and nine months ended September 30, 2023, respectively, compared to the same periods in the prior year, primarily driven by increases in marketing and promotional spend, primarily supporting the U.S. Pet Health business, employee-related expenses and travel and meeting expenses.
Amortization of Intangible Assets
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Amortization of intangible assets | $140 | $128 | 9% | $410 | $398 | 3% |
Amortization of intangible assets increased $12 million for the three and nine months ended September 30, 2023, compared to the same periods in the prior year, due to the addition of amortization of intangible assets recorded from the acquisitions of certain assets of NutriQuest and NutriQuest Brazil during the current year, as well as the impact of foreign exchange rates, primarily during the three months ended September 30, 2023.
Asset Impairment, Restructuring and Other Special Charges
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Asset impairment, restructuring and other special charges | $16 | $26 | (38)% | $91 | $152 | (40)% |
Asset impairment, restructuring and other special charges decreased $10 million for the three months ended September 30, 2023, compared to the prior year, primarily due to lower integration costs in the current year associated with the implementation of new systems, programs and processes resulting from the integration of Bayer
Animal Health. Asset impairment, restructuring and other special charges decreased $61 million for the nine months ended September 30, 2023, compared to the prior year, primarily due to the $59 million charge related to the expensing of an IPR&D asset licensed from BexCaFe during the prior year, which did not recur in the current year.
For additional information regarding our asset impairment, restructuring and other special charges, see Note 5. Asset Impairment, Restructuring and Other Special Charges to the condensed consolidated financial statements.
Goodwill Impairment
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Goodwill impairment | $1,042 | $— | NM | $1,042 | $— | NM |
We performed interim quantitative goodwill impairment tests as of September 30, 2023 and 2022. Our interim impairment test as of September 30, 2022, indicated no goodwill impairment, nor have any of the subsequent qualitative assessments through June 30, 2023. However, as discussed above, due principally to the sharp increase in long-term treasury rates in the third quarter of 2023, which led to an increased discount rate assumption, our quantitative impairment test resulted in a $1,042 million pre-tax impairment charge at September 30, 2023. For additional information regarding this goodwill impairment, see Note 11. Goodwill to the condensed consolidated financial statements.
Interest Expense, Net of Capitalized Interest
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Interest expense, net of capitalized interest | $72 | $60 | 20% | $210 | $179 | 17% |
Interest expense, net of capitalized interest increased $12 million and $31 million for the three and nine months ended September 30, 2023, respectively, compared to the same periods in the prior year, primarily due to higher interest rates on our outstanding variable-rate debt and rate increases on our Senior Notes driven by credit downgrades. The increase for the nine months ended September 30, 2023, compared to the prior year, was partially offset by $19 million of debt extinguishment charges recorded in 2022, which did not recur in the current year.
Other expense, net
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Other expense, net | $9 | $8 | 13% | $41 | $11 | NM |
Other expense, net for the three months ended September 30, 2023, primarily consisted of foreign exchange losses, inclusive of devaluation losses related to the hyperinflationary environments in Turkey and Argentina, in addition to an increase in the contingent consideration liability related to the NutriQuest acquisition. The increase due to these items was partially offset by milestone income related to a license agreement. Other expense, net for the nine months ended September 30, 2023, also consisted of a settlement provision of $15 million recorded in June 2023 related to the Seresto class action lawsuits (see Note 13. Commitments and Contingencies for further information) and mark-to-market adjustments on equity investments.
Income tax (benefit) expense
(Dollars in millions)
| Three Months Ended September 30, 2023 | 2022 | % Change | Nine Months Ended September 30, 2023 | 2022 | % Change | |
|---|---|---|---|---|---|---|
| Income tax (benefit) expense | $(1) | $21 | NM | $22 | $41 | (46)% |
| Effective tax rate | 0.2% | (47.7)% | (2.0)% | 234.3% |
We recognized an income tax benefit of $1 million for the three months ended September 30, 2023, compared to income tax expense of $21 million in the same period of the prior year. The effective tax rate was 0.2% for the three months ended September 30, 2023, as compared to the prior year effective tax rate of (47.7)%, and differed from the statutory income tax rate primarily due to the recognition of a goodwill impairment charge that was non-deductible in most of the impacted jurisdictions.
Income tax expense decreased $19 million for the nine months ended September 30, 2023, compared to the same period in the prior year, and the effective tax rate decreased to (2.0)%, compared to 234% in the prior year period. This decrease in the effective tax rate was primarily due to the recognition of a goodwill impairment charge that was non-deductible in most of the impacted jurisdictions. Income tax expense and the effective tax rate for the nine months ended September 30, 2022, included a $17 million income tax benefit reclassified from accumulated other comprehensive loss due to the termination of interest rates swaps during the nine months ended September 30, 2022.
Liquidity and Capital Resources
Our primary sources of liquidity are cash on hand, cash flows from operations and funds available under our credit facilities. As a significant portion of our business is conducted internationally, we hold a significant portion of cash outside of the U.S. We monitor and adjust the amount of foreign cash based on projected cash flow requirements. Our ability to use foreign cash to fund cash flow requirements in the U.S. may be impacted by local regulations and, to a lesser extent, the income taxes associated with transferring cash to the U.S. We intend to indefinitely reinvest foreign earnings for continued use in our foreign operations. As our business evolves, we may change that strategy, particularly to the extent we identify tax efficient reinvestment alternatives for our foreign earnings or change our cash management strategy.
We believe our primary sources of liquidity are sufficient to fund our short-term and long-term existing and planned capital requirements, which include working capital obligations, funding existing marketed and pipeline products, capital expenditures, business development in our targeted areas, short-term and long-term debt obligations, such as principal and interest payments, as well as interest rate swaps, operating lease payments, purchase obligations and costs associated with business integrations. As of September 30, 2023, we had cash and cash equivalents of $369 million and unused borrowing capacity on our Revolving Credit Facility of approximately $453 million. In addition, we have the ability to access capital markets to obtain debt financing for longer-term funding, if required. Further, we believe we have sufficient cash flow and liquidity to remain in compliance with our debt covenants.
Our ability to meet future funding requirements may be impacted by macroeconomic, business and financial volatility. As market conditions change, we will continue to monitor our liquidity position. However, a challenging economic environment or an economic downturn may impact our liquidity or ability to obtain future financing. See "Item 1A. Risk Factors - We may not be able to generate sufficient cash to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under our indebtedness, which may not be successful" in Part I of our 2022 Form 10-K.
Cash Flows
The following table provides a summary of cash flows from operating, investing and financing activities for the nine months ended September 30, 2023 and 2022:
(Dollars in millions)
| Net cash provided by (used for): | Nine Months Ended September 30, 2023 | 2022 | $ Change |
|---|---|---|---|
| Operating activities | $114 | $439 | $(325) |
| Investing activities | (134) | (103) | (31) |
| Financing activities | 56 | (465) | 521 |
| Effect of exchange-rate changes on cash and cash equivalents | (12) | (49) | 37 |
| Net increase (decrease) in cash and cash equivalents | $24 | $(178) | $202 |
Operating activities
Cash provided by operating activities decreased $325 million to $114 million for the nine months ended September 30, 2023, compared to $439 million for the nine months ended September 30, 2022. The decrease in cash from operating activities primarily related to a larger net loss, changes in operating assets and liabilities and a decrease of $150 million of proceeds from interest rate swap settlements year-over-year.
Investing activities
Cash used for investing activities was $134 million for the nine months ended September 30, 2023, compared to $103 million for the nine months ended September 30, 2022. The increase in cash used for investing activities was primarily driven by cash paid for the acquisitions of certain assets of NutriQuest and NutriQuest Brazil of $19 million during the nine months ended September 30, 2023.
Financing activities
Cash provided by financing activities was $56 million for the nine months ended September 30, 2023, compared to cash used for financing activities of $465 million for the nine months ended September 30, 2022. Cash provided by financing activities during the nine months ended September 30, 2023, reflected proceeds of $350 million from our Revolving Credit Facility, and $250 million from our Securitization Facility, largely offset by $388 million of repayments of long-term borrowings, inclusive of the $344 million repayment of our 4.272% Senior Notes due 2023, as well as repayments of $53 million on our Revolving Credit Facility and $97 million on our Securitization Facility. Cash used for financing activities of $465 million during the nine months ended September 30, 2022, primarily reflected the tender offer completed during the period, as well as net repayments on our Revolving Credit Facility and the repayment of indebtedness outstanding under our term loan B credit facility, partially offset by proceeds from the issuance of our incremental term facilities.
Description of Indebtedness
For a complete description of our existing debt and available credit facilities as of September 30, 2023 and December 31, 2022, see Note 10. Debt within Item 8, “Financial Statements and Supplementary Data,” of Part II of our 2022 Form 10-K. New developments are discussed in Note 8. Debt of this Form 10-Q.
Critical Accounting Policies and Estimates
The preparation of financial statements in accordance with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. Certain of our accounting policies are considered critical because these policies are the most important to the depiction of our financial statements and require significant, difficult or complex judgments, often requiring the use of estimates about the effects of matters that are inherently uncertain. Actual results that differ from our estimates could have an unfavorable effect on our financial position and results of operations. We apply estimation methodologies consistently from year to year. Such policies are summarized in Item 7, "Management's Discussion & Analysis of Results of Financial Condition and Results of Operations," of our 2022 Form 10-K. There were no significant changes or developments in the application of our critical accounting policies during the nine months ended September 30, 2023.
Goodwill Impairment Testing
We evaluate goodwill for impairment on an annual basis and when certain qualitative impairment indicators are present that would more likely than not reduce the fair value of our single reporting unit below its carrying amount.
In the third quarter of 2022, a significant change in our market capitalization relative to our book value, among other factors, triggered a goodwill impairment review. Based on our qualitative assessment, we concluded it was more likely than not that the fair value of our single reporting unit was less than its carrying value, and therefore, we performed a quantitative goodwill impairment test, which involved comparing the estimated fair value of our single reporting unit with its carrying value, including goodwill. We estimated the fair value of our single reporting unit using the income approach, concluding that the fair value of our single reporting unit exceeded the carrying amount by more than 20% as of September 30, 2022, and, therefore, no impairment existed with respect to our goodwill. Given that our market capitalization remained lower than our book value, we reevaluated our impairment testing from a qualitative perspective on a quarterly basis, with no change to our previous conclusion that no impairment existed through June 30, 2023. However, given the sharp increase in long-term treasury rates in the third quarter of 2023, we assessed our long-lived assets for impairment, concluding that qualitative impairment indicators (i.e., a triggering event) existed as of September 30, 2023, for certain indefinite-lived assets, including goodwill. As part of this assessment, we concluded it was more likely than not that the fair value of our single reporting unit was below its carrying amount, and as such, we performed an interim quantitative goodwill impairment test.
Significant management judgment was required in estimating our reporting unit’s fair value and in the creation of forecasts of future operating results that were used in the discounted cash flow method of valuation. These included, but were not limited to, estimates and assumptions regarding our future cash flows, revenue growth and other profitability measures such as gross margin and EBITDA margin; and the determination of an appropriate discount rate. We made these judgments based on our historical experience, relevant market size, historical pricing and expected industry trends. These assumptions are subject to change in future periods because of, among other things, additional information, financial information based on further historical experience, changes in competition, our investment decisions, volatility in foreign currency exchange rates, results of research and development and changes in macroeconomic conditions, including rising interest rates and inflation.
Due principally to the sharp increase in long-term treasury rates in the third quarter of 2023, which led to an increased discount rate assumption relative to prior interim assessments, our quantitative goodwill impairment test resulted in a $1,042 million pre-tax impairment charge as of September 30, 2023. While we believe the estimates and assumptions underlying our goodwill impairment test were reasonable in view of all available information, future changes in our discount rate assumption, whether driven by increases in long-term treasury rates or other factors, or future changes in other significant assumptions or the use of alternative estimates and assumptions, could have a significant impact on our reporting unit's estimated fair value and may expose us to further goodwill impairment losses.
Market risk
As filed, 2,437 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Foreign Exchange Risk
We operate on a global basis and are exposed to the risk that our earnings, cash flows and equity could be adversely impacted by fluctuations in foreign exchange rates. We are primarily exposed to foreign exchange risk with respect to net assets denominated in the Euro, British pound, Swiss franc, Brazilian real, Australian dollar, Japanese yen, Canadian dollar and Chinese yuan.
We generally identify hyperinflationary markets as those markets whose cumulative inflation rate over a three-year period exceeds 100%. Since 2018, we have concluded that our Argentina subsidiary is operating in a hyperinflationary market. As a result, we applied hyperinflationary accounting for our Argentina subsidiary and changed the functional currency to the U.S. dollar. During the first quarter of 2022, Turkey’s three-year cumulative inflation rate also exceeded 100%, and as such, we concluded that Turkey became a hyperinflationary economy for accounting purposes. As of April 1, 2022, we applied hyperinflationary accounting for our subsidiary in Turkey and changed its functional currency to the U.S. dollar. During the nine months ended September 30, 2023, revenue in Argentina and Turkey each represented less than 1% of our consolidated revenue, while assets held in Argentina and Turkey as of September 30, 2023, each represented less than 1% of our consolidated assets.
The application of hyperinflationary accounting for our subsidiaries in Argentina and Turkey has resulted in approximately $13 million of foreign currency related expense during the nine months ended September 30, 2023, which was included within other expense, net in the condensed consolidated statements of operations. In the future, we may incur larger currency devaluations, which could have a material adverse impact on our results of operations.
Interest Risk
Effective April 1, 2023, we transitioned the reference rates used in our credit facilities so that, as a result, our variable-rate debt is now exclusively indexed to Term SOFR. At September 30, 2023, we held interest rate swap agreements with a notional value of $3,800 million that had the economic effect of modifying this amount of our variable-rate debt to fixed-rate. When including variable-rate converted to fixed-rate through the use of interest rate swaps, as of September 30, 2023, approximately 76% of our long-term indebtedness bore interest at a fixed rate.
Controls and procedures
As filed, 1,972 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures. Under applicable SEC regulations, management of a reporting company, with the participation of the principal executive officer and principal financial officer, must periodically evaluate the company’s “disclosure controls and procedures,” which are defined generally as controls and other procedures of a reporting company designed to ensure that information required to be disclosed by the reporting company in its periodic reports filed with the SEC (such as this Form 10-Q) is recorded, processed, summarized and reported on a timely basis.
Our management, with the participation of Jeffrey N. Simmons, president and chief executive officer, and Todd S. Young, executive vice president and chief financial officer, evaluated our disclosure controls and procedures as of September 30, 2023. As disclosed in Item 9A of Part II of our 2022 Form 10-K, management concluded that a material weakness existed as of December 31, 2022, resulting from the ineffective review of the annual income tax provision, including the valuation allowance related to deferred tax assets. We have developed and are implementing a remediation plan which requires the effective operation of certain quarterly and annual controls. Therefore, the material weakness cannot be fully remediated until we assess the effectiveness of our internal control over financial reporting for the year ending December 31, 2023. Based on this evaluation, the chief executive officer and the chief financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures remained ineffective.
(b) Changes in Internal Controls. During the third quarter of 2023, there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting other than the aforementioned material weakness.
Risk factors
As filed, 7,425 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our risk factors are documented in Item 1A of Part I of our 2022 Form 10-K, which is incorporated herein by reference. Other than the revisions set forth below, there have been no material changes from the risk factors previously disclosed in the 2022 Form 10-K.
The following risk factors have been changed from the risk factors that were previously disclosed:
Unanticipated safety, quality or efficacy concerns or identified concerns associated with our products may harm our reputation and have an adverse impact on our performance.
Unanticipated safety, quality or efficacy concerns arise from time to time with respect to animal health products, whether or not scientifically or clinically supported, potentially leading to product recalls, withdrawals or suspended or reduced sales, as well as product liability and other claims. Regulatory actions based on these types of safety, quality or efficacy concerns could impact all, or a significant portion, of a product’s sales.
For example, lawsuits seeking actual damages, injunctive relief, and/or restitution for allegedly deceptive marketing have been filed against us arising out of the use of Seresto, a non-prescription flea and tick collar for cats and dogs, based on media reports alleging that the collar has caused injury and death to pets. Further, in 2021, the U.S. House of Representatives' then-subcommittee chair requested that we produce certain documents and information related to the Seresto collar, made a request to temporarily remove Seresto collars from the market and, during a hearing at which our President and Chief Executive Officer (CEO) testified, again called for removal of the collars from the market.
Since that time, on July 13, 2023, the EPA announced the completion of its comprehensive, multi-year review of the Seresto flea and tick collar and confirmed the continued registration of the collar. However, if any similar claims with respect to our products are resolved adversely to us, or if a regulatory agency determines that a recall or cancellation of registrations of any of our products is necessary, such action could cause harm to our reputation, reduce our product sales, result in monetary penalties and other costly remedies against us, and could therefore have a material adverse effect on our business, financial condition and results of operations.
In addition, we depend on positive perceptions of the safety, quality and efficacy of our products, and animal health products in general, by food producers, veterinarians and pet owners. Any concern as to the safety, quality or efficacy of our products, whether actual or perceived, may harm our reputation. These concerns, including those relating to Seresto, and the related harm to our reputation could materially adversely affect our business, financial condition and results of operations, regardless of whether such reports are accurate.
Changes in our credit rating could increase our interest expense and restrict our access to, and negatively impact the terms of, current or future financings or trade credit.
Credit rating agencies continually revise their ratings for the companies that they follow, including us. Credit rating agencies also evaluate our industry as a whole and may change their credit ratings for us based on their overall view of our industry. We cannot be sure that credit rating agencies will maintain their ratings on us and certain of our debt. The acquisition of Bayer Animal Health had a negative impact on our credit ratings, leading to higher borrowing expenses. Additionally, S&P, Moody's and Fitch downgraded our credit ratings in February, March and April 2023, respectively. Because the ratings of certain of our senior unsecured notes have been downgraded, we have been required to pay additional interest under the senior unsecured notes. Any further downgrades could result in requirements to pay additional interest under the 4.900% Senior Notes due 2028. Moreover, any decision to downgrade our ratings could restrict our access to, and negatively impact the terms of, current or future financings and trade credit extended by our suppliers of raw materials or other vendors.
Changes in interest rates may adversely affect our earnings and/or cash flows.
During the first quarter of 2023, certain of our credit facilities bore interest at variable interest rates that used the London Inter-Bank Offered Rate (LIBOR) as a benchmark rate. Effective April 1, 2023, and in accordance with the provisions outlined in our underlying credit agreements, we transitioned the reference rate used in our credit facilities from LIBOR to Term SOFR.
Term SOFR measures the cost of borrowing cash overnight, collateralized by U.S. Treasury securities, and is based on directly observable U.S. Treasury-backed repurchase transactions. While this change did not have a material impact on our condensed consolidated financial statements, we continue to be exposed to the risk of rising interest rates, given our level of variable-rate indebtedness. Term SOFR rate increases over the course of 2023 have led to an increase in both our interest expense and cash paid for interest. Additionally, the increased interest rate environment, particularly long-term treasury rates, played a critical role in the goodwill impairment charge of $1,042 million we recorded during the third quarter of 2023. Any further increases in Term SOFR or other benchmark rates, including long-term treasury rates, would expose us to additional interest rate risk, additional expense and the potential for additional future impairments. We are also exposed to the risk of rising interest rates to the extent we fund our operations with short-term or variable-rate borrowings.
We use machine learning and artificial intelligence (AI) in our business, and challenges with properly managing its use could result in competitive or reputational harm and legal liability and adversely affect our results of operations.
We use AI in multiple ways in our business and continue to expand the use of AI in our operations. Given that machine learning and AI are new and rapidly evolving technologies, their use presents a number of operational, compliance and reputational risks. AI algorithms are currently known to sometimes produce unexpected results or behave in unpredictable ways that can generate irrelevant, nonsensical, deficient, factually inaccurate or biased content and results. Accordingly, AI presents emerging operational, legal and ethical issues, and if our use of AI becomes controversial, we may experience reputational harm to our brand, competitive harm or legal liability. At the same time, our competitors may incorporate AI into their operations more quickly than we do or with more successful outcomes, which would also harm our business. We also expect there will be new laws or regulations concerning the use of AI technology, which might be burdensome to comply with and may limit our ability to use this technology. We might not be able to attract and retain the talent to support our AI technology initiatives and maintain our systems. Any disruption or failure in our AI systems or those of third parties on whom we rely could result in delays and operational challenges, and the various operational, compliance and reputational issues could adversely affect our business and results of operations.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2023-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2023-07-01 to 2023-09-30 | $1.07bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2023-01-01 to 2023-09-30 | $3.38bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2023-07-01 to 2023-09-30 | $487.0m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2023-01-01 to 2023-09-30 | $1.42bn | us-gaap:CostOfGoodsAndServicesSold |
| Research and development | 3 months2023-07-01 to 2023-09-30 | $86.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2023-01-01 to 2023-09-30 | $248.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2023-07-01 to 2023-09-30 | $313.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2023-01-01 to 2023-09-30 | $993.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Interest expense | 3 months2023-07-01 to 2023-09-30 | $72.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2023-01-01 to 2023-09-30 | $210.0m | us-gaap:InterestExpense |
| Income tax | 3 months2023-07-01 to 2023-09-30 | −$1.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2023-01-01 to 2023-09-30 | $22.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2023-07-01 to 2023-09-30 | −$1.10bn | us-gaap:NetIncomeLoss |
| Net income | 9 months2023-01-01 to 2023-09-30 | −$1.09bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2023-07-01 to 2023-09-30 | −$2.22 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2023-01-01 to 2023-09-30 | −$2.21 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2023-07-01 to 2023-09-30 | −$2.22 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2023-01-01 to 2023-09-30 | −$2.21 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2023-07-01 to 2023-09-30 | 492,700,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2023-01-01 to 2023-09-30 | 492,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2023-01-01 to 2023-09-30 | $114.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Cash and equivalents | At period end2023-09-30 | $369.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2023-09-30 | $3.56bn | us-gaap:AssetsCurrent |
| Total assets | At period end2023-09-30 | $14.34bn | us-gaap:Assets |
| Current liabilities | At period end2023-09-30 | $1.26bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2023-09-30 | $8.21bn | us-gaap:Liabilities |
| Long-term debt | At period end2023-09-30 | $5.87bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2023-09-30 | $39.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2023-09-30 | $6.13bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001739104-23-000023. Last ingested by Listed: Nov 13, 2026, 16:18 ET. Listed shows no prices and gives no investment advice.